TriSalus Life Sciences Reports First Quarter 2026 Results
TriSalus Life Sciences, Inc. reported its financial results for the first quarter of 2026, highlighting significant commercial and clinical progress aimed at long-term growth. The company focuses on integrating novel delivery technology with standard therapies and has an investigational immunotherapeutic designed to transform treatment for patients with solid tumors.
DENVER–(BUSINESS WIRE)–TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended March 31, 2026, and provided an operational update. “The first quarter marked an important strategic inflection point for TriSalus as we significantly strengthened our c